摘要
目的:观察美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者的效果。方法:选取86例冠心病心力衰竭患者为研究对象,按照随机数字表法分成对照组(n=43)和研究组(n=43)。两组均给予常规治疗,在此基础上,对照组采用曲美他嗪治疗,研究组在对照组基础上联合美托洛尔治疗,比较两组临床疗效、治疗前后生命体征[收缩压(SBP)、舒张压(DBP)、心率(HR)]、心功能指标[左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)]水平,以及不良反应发生率。结果:研究组治疗总有效率为95.35%(41/43),高于对照组的79.07%(34/43),差异有统计学意义(P<0.05);治疗后,两组SBP、DBP、HR水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组LVEF水平均高于治疗前,且研究组高于对照组,两组LVESD、LVEDD水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者可提高治疗总有效率,改善生命体征和心功能指标水平,效果优于单纯曲美他嗪治疗。
Objective:To observe effects of Metoprolol combined with Trimetazidine on patients with coronary heart disease and heart failure.Methods:86 patients with coronary heart disease and heart failure were selected as the research objects and were divided into control group(n=43)and study group(n=43)according to the random number table method.Both groups were given conventional treatment.On this basis,the control group was treated with Trimetazidine,while the study group was treated with Metoprolol on the basis of that of the control group.The clinical efficacy,the vital signs[systolic blood pressure(SBP),diastolic blood pressure(DBP),heart rate(HR)],the cardiac function indicator levels[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)]and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 95.35%(41/43),which was higher than the control group of 79.07%(34/43),and the difference was statistically significant(P<0.05).After the treatment,SBP,DBP and HR in the two groups were lower than those before the treatment,those of the study group were lower than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of LVEF in the two groups were higher than those before the treatment,that of the study group was higher than that of the control group;the levels of LVESD and LVEDD in the two groups were lower than those before the treatment,those of the study group was lower than those of the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Metoprolol combined with Trimetazidine in the treatment of the patients with coronary heart disease and heart failure can improve the total effective rate of treatment,and improve the levels of vital signs and cardiac function indicators.Moreover,it is superior to single Trimetazidine treatment.
作者
田伟
TIAN Wei(Department of Internal Medicine of Lankao County Central Hospital,Kaifeng 475300 Henan,China)
出处
《中国民康医学》
2022年第12期23-25,共3页
Medical Journal of Chinese People’s Health
关键词
曲美他嗪
美托洛尔
冠心病
心力衰竭
心功能
生命体征
不良反应
Trimetazidine
Metoprolol
Coronary heart disease
Heart failure
Cardiac function
Vital sign
Adverse reaction
